Research programme: Alzheimer's disease therapies - Alzhyme

Drug Profile

Research programme: Alzheimer's disease therapies - Alzhyme

Alternative Names: ANA-1; ANA-5

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alzhyme
  • Developer Alzhyme; ANSTO Radiopharmaceuticals and Industrials; CSIRO
  • Class Peptides; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; Superoxide dismutase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in Australia (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease(Diagnosis) in Australia (PO)
  • 16 Apr 2010 Preclinical development is ongoing In Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top